Apelin elevates blood pressure in ICR mice with L-NAME-induced endothelial dysfunction

Molecular Medicine Reports

Volumn 7, Issue 5, 2013, Pages 1371-1375

  Nagano, Katsumasa ^a   Ishida, Junji ^a   Unno, Madoka ^a   Matsukura, Tanomu ^a   Fukamizu, Akiyoshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Apelin; APJ; Endothelial dysfunction; Impaired vasodilatation; L NAME; Mice; Vasopressor action

Indexed keywords

APELIN; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; AORTA; BLOOD PRESSURE; BODY WEIGHT; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HYPERTENSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED ICR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; SYSTOLE; VASOCONSTRICTOR AGENTS; VASODILATION;

MUS;

EID: 84875984219     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1378     Document Type: Article

References (19)

1. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H and Fujino M: Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251: 471-476, 1998.
2. Kleinz MJ, Skepper JN and Davenport AP: Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 126: 233-240, 2005.
3. Cheng X, Cheng XS and Pang CC: Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 470: 171-175, 2003.
4. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R, Shiota N, Okunishi H, Kihara M, Umemura S, Sugiyama F, Yagami K, Kasuya Y, Mochizuki N and Fukamizu A: Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 279: 26274-26279, 2004.
5. Katugampola SD, Maguire J, Matthewson SR and Davenport AP: [125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 132: 1255-1260, 2001.
6. Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, Fukamizu A, Kitamura H and Umemura S: Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 26: 1267-1272, 2006.
7. Cohn JN: Vascular wall function as a risk marker for cardiovascular disease. J Hypertens Suppl 17: 41-44, 1999.
8. Rubanyi GM: The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 22 (Suppl 4): S1-S14, 1993.
9. Baylis C, Mitruka B and Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90: 278-281, 1992.
10. Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Katz SE, Douglas PS and Lorell BH: Chronic NG-nitro-L-arginine methyl ester-induced hypertension novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 101: 423-429, 2000.
11. Dornas WC and Silva ME: Animal models for the study of arterial hypertension. J Biosci 36: 731-737, 2011.
12. Suda O, Tsutsui M, Morishita T, Tanimoto A, Horiuchi M, Tasaki H, Huang PL, Sasaguri Y, Yanagihara N and Nakashima Y: Long-term treatment with Nω-nitro-l-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient. Circulation 106: 1729-1735, 2002.
13. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K and Murakami K: Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 268: 11617-11621, 1993.
14. Hobbs AJ and Gibson A: L-NG-nitro-arginine and its methyl ester are potent inhibitors of non-adrenergic, non-cholinergic transmission in the rat anococcygeus. Br J Pharmacol 100: 749-752, 1990.
15. Widlansky ME, Gokce N, Keaney JF Jr and Vita JA: The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42: 1149-1160, 2003.
16. Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL and Eriksson P: Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc Res 59: 169-180, 2003.
17. Nürnberger W, Michelmann I, Burdach S and Göbel U: Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 76: 61-65, 1998.
18. De Gennaro Colonna V, Rossoni G, Rigamonti A, Bonomo S, Manfredi B, Berti F and Muller E: Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in L-NAME-treated rats. Eur J Pharmacol 450: 61-66, 2002.
19. Wang LY, Zhang DL, Zheng JF, Zhang Y, Zhang QD and Liu WH: Apelin-13 passes through the ADMA-damaged endothelial barrier and acts on vascular smooth muscle cells. Peptides 32: 2436-2443, 2011.